|
FDA Places Clinical Hold on Second Idenix Hepatitis Drug
The FDA has placed a “precautionary” clinical hold on Idenix Pharmaceutical’s next-generation nucleotide polymerase inhibitor, IDX19368, being developed to treat hepatitis C (HCV) infection.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives